Regenxbio Inc. has appointed Mitchell Chan as Executive Vice President and Chief Financial Officer, effective today.
 
A veteran finance executive and operating partner in the biotechnology industry, Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years. 
 
He succeeds Vit Vasista, who served as Executive Vice President and Chief Financial Officer since 2009. Vasista will serve as an advisor to the Company through January 3, 2025, to support a smooth transition.
 
This news comes months after the company promoted Curran Simpson, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board of Directors.
 
“We are excited to welcome Mitchell at this exciting time for Regenxbio,” said Curran Simpson. “Mitchell has an extensive track record of successfully driving finance organizations to support growth and deep expertise in strategic planning and capital markets. We look forward to working with Mitch as we continue to advance our product pipeline towards commercialization and deliver value to shareholders.”

Experience 

Chan brings nearly two decades of biopharmaceutical financial leadership experience to Regenxbio.
 
Most recently, he served as Operating Partner at Catalio Capital Management, an investment firm focused on innovative biotechnology companies, where he served as acting CFO of several portfolio companies and advised on the firm’s investments. From 2018 to 2021, Chan was CFO of Viela Bio, Inc., where he oversaw a successful IPO and $3B acquisition by Horizon Therapeutics. Prior to Viela, he held various financial and investor relations leadership roles at AstraZeneca and Genentech-Roche, among other companies. He has served on the Board of Directors of Avalo Therapeutics since 2021.
 
Chan holds an M.S. in Medical Biophysics, an M.B.A, and a B.S. in Biochemistry from the University of Toronto.
 
“With several key catalysts on the horizon, I am excited to join Regenxbio at this important juncture,” said Chan. “I look forward to leveraging my financial and industry experience to support the Company’s transition to commercialization and continue the development of next-generation gene therapies for debilitating diseases that lack sustainable or effective treatment options for patients in need.”